Masakazu Toi

TL;DR: Docetaxel seems to be effective in patients with advanced/recurrent breast cancer who are refractory to anthracycline therapy, and Grade 3-4 leukocytopenia and neutropenia were frequently seen in patients who had received anthrACYcline of more than 500 mg/body as first-line chemotherapy.

TL;DR: In this paper , the authors presented efficacy results from a pre-specified overall survival interim analysis (OS IA2) which was planned to occur 2 years after the primary outcome analysis, showing that the clinically meaningful benefit of adjuvant abemaciclib added to ET in HR+, HER2-, node-positive, high risk EBC persists beyond completion of cancer therapy.

TL;DR: A novel method for efficiently modeling and inferring the physical parameters, including gravity, Young's modulus, Poisson’s ratio, etc, which are important elements for handling the biomechanical deformations of breast with finite element model is presented.

TL;DR: Non-Gaussian diffusion may be associated with prognosis in invasive breast cancer and may be a marker to help identify patients at an elevated risk of distant metastasis, which could guide subsequent treatment.

TL;DR: In this article, the authors evaluated the safety and efficacy of weekly docetaxel (weekly TXT) in cases of advanced or recurrent breast cancer, 31 patients were enrolled in this pilot study of weekly TXT given at 25 mg/m2/w.